Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,041,250
  • Shares Outstanding, K 71,292
  • Annual Sales, $ 301,030 K
  • Annual Income, $ -361,920 K
  • 60-Month Beta 2.08
  • Price/Sales 30.40
  • Price/Cash Flow N/A
  • Price/Book 8.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -2.12
  • Number of Estimates 9
  • High Estimate -0.79
  • Low Estimate -3.50
  • Prior Year -0.44
  • Growth Rate Est. (year over year) -381.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
124.70 +1.19%
on 03/19/19
155.23 -18.71%
on 02/27/19
-14.08 (-10.04%)
since 02/19/19
3-Month
95.21 +32.53%
on 12/24/18
155.23 -18.71%
on 02/27/19
+23.07 (+22.37%)
since 12/19/18
52-Week
70.50 +78.98%
on 04/04/18
176.50 -28.51%
on 06/19/18
+47.40 (+60.17%)
since 03/19/18

Most Recent Stories

More News
Sarepta Therapeu Set to Possibly Rebound After Yesterday's Selloff of 1.85%

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $129.51 to a high of $130.15. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of...

SRPT : 125.52 (-1.03%)
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

--Zilucoplan extended release (XR) achieves greater than one week of target drug concentrations in non-human primates following a single subcutaneous injection, supporting once weekly or less frequent...

RARX : 27.08 (+0.78%)
SRPT : 125.52 (-1.03%)
SmarTrend Watching for Potential Rebound in Shares of Sarepta Therapeu After 9.52% Loss

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $134.62 to a high of $140.00. Yesterday, the shares fell 9.5%, which took the trading range below the 3-day low of...

SRPT : 125.52 (-1.03%)
Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT),...

ELLI : 98.71 (-0.23%)
SRPT : 125.52 (-1.03%)
AKCA : 29.56 (-1.86%)
SBH : 18.62 (+2.65%)
BCRX : 7.96 (-1.97%)
DHR : 129.55 (+1.16%)
Shares of Stemline Therape Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (STML , ALNY , SRPT , ESPR , PTCT )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SRPT : 125.52 (-1.03%)
STML : 13.35 (+3.49%)
ALNY : 88.34 (-2.11%)
Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 2,604,167 shares...

SRPT : 125.52 (-1.03%)
Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $350,000,000 in...

SRPT : 125.52 (-1.03%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2019, that were previously approved by the Compensation Committee...

SRPT : 125.52 (-1.03%)
Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up

Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.

CELG : 89.04 (+1.19%)
GHDX : 74.84 (+0.82%)
SRPT : 125.52 (-1.03%)
BMRN : 92.31 (-1.12%)
CENTOGENE Announces Strategic Collaboration with Sarepta Therapeutics

CENTOGENE today announced a 12-month strategic collaboration with Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for the identification of patients with Duchenne muscular dystrophy (DMD)...

SRPT : 125.52 (-1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 132.22
1st Resistance Point 129.52
Last Price 125.52
1st Support Level 124.71
2nd Support Level 122.60

See More

52-Week High 176.50
Fibonacci 61.8% 136.01
Last Price 125.52
Fibonacci 50% 123.50
Fibonacci 38.2% 110.99
52-Week Low 70.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar